Local Hemodynamic Forces After Stenting Implications on Restenosis and Thrombosis by Ng, J et al.
 
 
Local Hemodynamic Forces After Stenting: Implications on Restenosisand 
Thrombosis  
 
Jaryl Ng1; Christos V. Bourantas2,3; Ryo Torii4; Ang Hui Ying1; Erhan Tenekecioglu5;  
Patrick W. Serruys5,6; Nicolas Foin1,7* 
 
Affiliations: 
1. National Heart Centre Singapore, Singapore 
2. Department of Cardiovascular Sciences, University College London, London, United Kingdom 
3. Department of Cardiology, Barts Health NHS Trust, London, United Kingdom 
4. Department of Mechanical Engineering, University College London, London, United Kingdom 
5. Thoraxcenter, Erasmus MC, Rotterdam Erasmus University, Netherlands 
6. National Heart & Lung Institute, Imperial College London, United Kingdom 
7. Duke-NUS Medical School, National University of Singapore, Singapore 
* Corresponding author 
Adj. A/Prof. Nicolas Foin, PhD 
National Heart Research Institute Singapore 







• Stent restenosis and thrombosis are major complications that can develop after percutaneous coronary 
intervention and are associated with risks of reintervention and potential acute coronary events. 
• Hemodynamic forces trigger biological pathways that are involved in both stent thrombosis and restenosis. 
• Effort should be made to design drug-eluting stents and bioresorbable scaffolds that will have an optimal 
hemodynamic profile so as to improve their safety and reduce the incidence of stent/scaffold related 
adverse events. 







Local hemodynamic forces are well-known to modulate atherosclerotic evolution, which remains one of the 
largest cause of death worldwide. Percutaneous coronary interventions with stent implantation restores blood 
flow to the downstream myocardium and is only limited by stent failure caused by restenosis, stent thrombosis, 
or neoatherosclerosis. Cumulative evidence has shown that local hemodynamic forces affect restenosis and 
the platelet activation process, modulating the pathophysiological mechanisms that lead to stent failure. This 
article first covers the pathophysiological mechanisms through which wall shear stress regulates arterial 
disease formation/neointima proliferation and the role of shear rate on stent thrombosis. Subsequently, the 
article reviews the current evidence on (1) the implications of stent design on the local hemodynamic forces, 
and (2) how stent/scaffold expansion can influence local flow, thereby affecting the risk of adverse events. 
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Advances in stent technology, drug polymer biocompatibility,  and design have improved the safety and 
efficacy of coronary stent devices. Despite these advances, restenosis and device thrombosis remain a major 
concern and are still affecting longterm clinical outcomes.1 Randomized trials and clinical registries show that 
the rate of stent thrombosis is <1% after 1 year, and the restenosis rates remain at ≈5%.2 Nevertheless, the 
cumulative incidences of these events in the long term still remain substantial. Hence, it is crucial to identify 
the causes of stent/scaffold failure and understand how the hemodynamic environment impacts clinical 
outcomes postpercutaneous coronary intervention (PCI). With current high-resolution intravascular imaging, 
geometrically accurate representation of patient-specific coronary anatomy can be reconstructed for blood 
flow simulation, enabling precise endothelial shear stress (ESS) maps to be generated (Figure 1). Patient-
specific biomechanical forces can then be quantified to investigate the pathophysiological implications of the 
flow patterns in stented/scaffolded segments and their role in neointimal hyperplasia and device thrombosis.4 
This article will first define the metrics of local hemodynamics and introduce the main pathophysiological 
mechanisms, followed by a summary on the evidence about the role of the local hemodynamics on stent 
thrombosis and restenosis. 
 
Metrics of Local Hemodynamics 
Shear Rate 
Shear rate is defined as the local velocity gradient between adjacent blood flow streamlines (Figure 2) and 
provides a quantitative representation of local flow disturbance. Shear rate is also one of the main regulators 
of platelet activation and thrombosis.6,7 In medium- to large-sized arteries, physiological shear rate falls within 
the range of 100 to 1000 s−1.8 In silico and in vivo studies have shown that in stented/scaffolded segments, 
the rigid protruding and malapposed struts create flow obstructions that disrupt blood flow, resulting in flow 
separation and shear rates >2000 s−1.9–12 
Endothelial Shear Stress 
ESS is estimated by multiplying the shear rate at the wall surface with the viscosity of blood (Figure 2) and 
represents the tangential frictional stress on the vessel wall imposed by the flowing blood. In vivo evaluations 
of ESS using computational fluid dynamic methods have shown that its distribution predicts atherosclerotic 
lesion development.13–17 Low and oscillatory ESS is a known modulator of arterial wall physiology, specifically 
via impaired endothelial cell function where low ESS has been shown to regulate gene expression and vascular 
proinflammatory response through multiple mechanotransduction pathways.18,19 
 
Hemodynamics Impact on Disease Process 
Low ESS and Arterial Disease Development 
The endothelium senses changes in ESS via several mechanotransduction processes that involve 
activation/release of signalling proteins in endothelial cells and smooth muscle cells, which in turn regulate 
vessel wall physiology.20–25 The type and magnitude of response are determined by the magnitude and 
direction of ESS.26 Experimental studies have demonstrated that low ESS (<10 dynes/cm2) causes misalignment 
of the endothelium27,28 and disruption of cell–cell junctions.29–31 This increases the permeability of the 
endothelium to circulating lipids and inflammatory regulators.32–34 In addition, low ESS decreases vasodilator,25 
fibrinolytics,35 and antioxidants36 and increases expression of cell adhesion molecules,22 growth factors,37 
2 
 
vasoconstrictors,38 oxidative species,39 proteolytic enzymes,40 and acute inflammatory mediators.41 This leads 
to endothelial dysfunction, vessel inflammation, and smooth muscle cells proliferation, contributing to plaque 
growth and arterial expansive remodeling.14 The behavior of smooth muscle cells is regulated by the 
interaction with endothelial cells but also by mechanical forces, such as shear stress. ESS leads to the release 
of platelet-driven growth factor and transforming growth factor which causes smooth muscle cell proliferation 
and migration, subsequently resulting in neointimal hyperplasia and restenosis. 14,26,38 When there is no 
endothelium, Liu and Goldman42 demonstrated that smooth muscle cell migration is significantly suppressed 
under laminar flow conditions compared with regions that are exposed to recirculating and unsteady flow. 
Shear modification has been shown to modulate plaque progression and the degree of inflammation in animal 
models.18,43 Low and oscillating ESS has been reported to accelerate vulnerable atherosclerotic plaque 
formation.18,19 In a recent experimental study using intracoronary shear-modifying stents in 
hypercholesterolemic pigs, Pedrigi et al44 reported an ≈3- fold increase in plaque burden distal to the shear-
modifying stents compared with both proximal segment and the control arteries. Advanced coronary plaques 
were colocated mostly downstream of the shear-modifying stents, in regions of low ESS.44 Although low ESS 
alone has been shown to increase plaque progression, a combination of low and oscillatory ESS is considered 
to be particularly atherogenic. Flow simulations on intravascular ultrasound–derived vessels of patients with 
coronary artery disease demonstrated that low and oscillatory ESS can cause plaques to evolve into a more 
vulnerable phenotype compared with low ESS only because of more inflammation and necrotic core 
progression.45 
The Table summarizes studies that have examined the impact of low ESS on atherosclerosis and restenosis. 
Most studies associated regions of low ESS with increased plaque burden or atherosclerosis plaque 
progression. 
 
Low ESS and Restenosis Post-PCI 
Studies have reported that there is also an inverse correlation between baseline ESS and neointimal thickness 
at follow-up (ie, low ESS increases neointimal proliferation). In the study conducted by Wentzel et al,50 blood 
flow simulation was performed in segments implanted with bare metal stents (BMS). The ESS distribution was 
estimated on the reconstructed surfaces of stented vessel segments after implantation and at 6-month follow-
up. An inverse association was found between baseline ESS and neointima formation at 6-month follow-up.50 
These findings were confirmed in several other studies.3,50,52,53,58,59 Papafaklis et al53 investigated the 
implications of the local hemodynamic forces on neointimal response in BMS and first-generation drug-eluting 
stents (DES). The study reported an inverse correlation between ESS and neointima response in BMS while in 
DES vessels, wall response was shown to depend on the antiproliferative drug. Sirolimus seems to reduce the 
amount of positive cell cycle regulators and increase the amount of cell cycle inhibitors, leading to inhibited 
cell migration, proliferation, and desensitization of the cells to the effects of low ESS.  
The PREDICTION study (Prediction of Progression of Coronary Artery Disease and Clinical Outcome Using 
Vascular Profiling of Shear Stress and Wall Morphology) was the largest ESS study investigating the 
implications of the local hemodynamic forces on the healing response after BMS and first-generation DES in 
vivo. The relationship between postprocedural ESS and neointimal in-stent hyperplasia was investigated by 
comparing the 3-dimensional reconstructed stented segments of 374 patients at baseline immediately after 
stent implantation and 6- to 10-month follow-up.17,57 The study demonstrated an inverse relationship between 
ESS and neointima response in BMS while in DES, the neointima tissue was too limited for assessment of the 
association between ESS and neointima tissue.57 Bourantas et al56 have also investigated the association 
between ESS and neointima proliferation using serial intravascular ultrasound imaging in 43 patients 
3 
 
implanted with either BMS or biolimus-eluting stents at baseline and 13-month follow-up. Negative 
correlations were noted between ESS and neointima thickness in both groups. There was also a negative 
correlation between ESS and the percentage of neointimal necrotic core component (P=0.015) in BMS while 
the limited neointima formation impeded the evaluation of the effect of ESS on neointima characteristics in 
DES. 
Optical coherence tomography–based reconstruction was used to assess the implications of the ESS on 
neointima response in 12 patients implanted with an everolimus-eluting bioresorbable vascular scaffold (BVS; 
Absorb BVS; Abbott Vascular, Santa Clara, CA). In this analysis, the optical coherence tomography data 
acquired at baseline and 1-year follow-up were used to model vessel geometry.55 The authors showed that 
the protruding struts resulted in low ESS in the areas between the struts and high ESS at the top of the struts. 
A strong negative correlation was observed between baseline ESS and neointimal thickness at follow-up; and 
increased neointima proliferation was found in the areas between the struts where the ESS was. This resulted 
in a smoothening of the rugged luminal surface and a homogenization of the ESS at 2-year follow-up.55 
Recently, Torii et al60 evaluated the implications of the local flow patterns on neoatherosclerotic lesion 
formation in 35 patients implanted with either BMS or DES. The patients were admitted with coronary events 
attributed to stent failure and had neoatherosclerotic lesions based on optical coherence tomography images. 
An inverse association was noted between ESS and the incidence and burden of lipid-rich neoatherosclerotic 
tissue (P<0.001). Segments exposed to low ESS (<1 Pa) were more likely to exhibit macrophage accumulations, 
thrombus, or neointima discontinuities compared with those exposed to normal or high ESS (P<0.001). These 
results indicate that local ESS also plays a role in the regulation of neoatherosclerosis lesion formation in 
stented segments60 (Figure 3). 
 
Shear Rate Modulation of Platelet Activation and Thrombosis 
Shear rate seems to play an important role on vessel physiology and determines the concentration of platelets 
and adhesion proteins near the vessel wall. In segments exposed to high shear rate, red blood cells cause 
platelets displacement toward the vessel wall via a process called margination. The accumulation of platelets 
and adhesion proteins near the vessel wall creates a prothrombotic environment.61–63 
When adhesion proteins like Von Willebrand factor and fibrinogen come in contact with a thrombogenic 
surface (ie, ruptured plaques and stent struts), a clot cascade is triggered. Once the adhesion proteins attach 
to the thrombogenic surface, they stimulate activated platelets to bind to the surface. At high shear rates, the 
globular structure of the Von Willebrand factor elongates into a string structure,64–67 increasing the amount of 
platelet binding sites on the molecule. With high shear rates (≈10 000 s−1), Von Willebrand factor strings 
combine to form nets that further increase the amount of platelet binding sites by ≈10 000×.66,68 The attracted 
platelets are exposed to high ESS, which shortens their activation time.69 As the thrombus grows, more Von 
Willebrand factor nets are formed which subsequently increase the number of bound platelets. This positive 




Stent-Induced Hemodynamic Changes During PCI 
In the BMS era, excessive neointimal proliferation was a major drawback that caused early restenosis.70 With 
the introduction of DES, the occurrence of restenosis has been significantly reduced. However, in-stent 
thrombosis has remained an issue observed at both short- and long-term follow-up. It was reported that strut 
dimensions and the distance of the struts from the vessel wall affect stent thrombogenicity more than the 
presence of drug coatings.11 Although stent thrombosis may have a relatively low incidence (0.6%–3.4%),71 it 
is still the most feared complication after PCI because of the associated mortality risk for the patients.72 Studies 
have revealed that the major causes of early stent thrombosis (<30 days) are largely because of stent 
underexpansion and malapposition while late stent thrombosis (>30 days) is found frequently with late 
remodeling, stent strut malapposition, and delayed endothelial coverage.71 
Stent Design 
Stent design has an impact on the flow dynamics in stented segments. Strut thickness, in particular, is a major 
factor affecting local shear rate and ESS post-PCI. Large strut thickness increases the amount of foreign 
material in the lumen and leads to flow disturbances, flow separation, and areas of recirculation zones, 
thereby increasing the risk of stent thrombosis.9–12,55,73 Models have shown that the maximal distance between 
the helical rings should be at least 6× the strut thickness to recover any laminar flow in the interstrut zones.74 
Smaller strut thickness can improve re-endothelialization and reduce peristrut inflammation and fibrin 
deposition.75–77 In the BMS era, clinical studies have reported improved outcomes in patients implanted with 
thin strut stents.78–81 Flow separation distance was also found to be longer in nonstreamlined struts 
(rectangular) compared with streamlined struts (circular/ovoid).82 Polymer coating is another essential part of 
stent design that can affect stent’s thrombogenicity. Otsuka et al83 observed in an ex vivo model that the 
fluoropolymer-coated Xience DES showed a significantly lower percentage of a thrombusoccupied areas 
compared with a DES with contemporary biodegradable coatings. Kolandaivelu et al11 investigated the 
implications of stent design and drug coating on the incidence of stent thrombosis by deploying DES and BMS 
with identical design but different strut thickness in ex vivo perfusion models. Results indicated that DES with 
a biocompatible drug coating had a 0.65-fold lower thrombogenicity compared with BMS while thicker struts 
stents were 1.5× more thrombogenic than thin strut stents with the same design.11 
Current bioresorbable scaffolds (BRS) have thicker struts (≥150 μm) compared with second-generation 
metallic DES (≤100 μm). One of the most widely examined BRS is the Abbott Vascular’s Absorb BVS, which is 
fabricated from a poly-L-lactic acid backbone. The Absorb BVS has a strut thickness of 156 μm and a width of 
190 μm while the Xience DES has a total strut thickness of 89 μm. Because of the lower elastic modulus and 
tensile strength of the bioresorbable materials, thicker struts are often required in BRS to achieve a radial 
force similar to that of conventional metallic platforms.84–86 
Studies have shown more extensive neointimal hyperplasia and late lumen loss in BRS compared with DES at 
showed >50% increase in maximum shear rate values with protruding stent struts10 compared with embedded 
struts. These flow patterns around indented struts are commonly associated with increased platelet 
adhesion11,93 and inflammatory response,94 as well as reduced re-endothelialization.75,95–97 short-term follow-
up.85,87–91 Large strut size and other factors, such as scaffold underexpansion, incomplete scaffolding, and the 
acidic environment during polymer dissolution, may play a role in causing late lumen loss in BRS device. It has 
been hypothesized that the large strut profile of current generation of BRS is harder to embed in the tissue, 
hence creating a larger obstacle for blood flow.92 Computational flow simulations showed >50% increase in 
maximum shear rate values with protruding stent struts10 compared with embedded struts. These flow 
patterns around indented struts are commonly associated with increased platelet adhesion11,93 and 




Stent underexpansion is usually quantified by the postprocedural diameter stenosis in quantitative coronary 
angiography and intravascular imaging. This is done by measuring the minimum lumen area of the 
stent/scaffold segment and relative percentage area stenosis. Underexpansion can be caused by inappropriate 
lesion preparation and postdilatation of the implanted stent/scaffold with too small balloons or insufficient 
pressure, particularly in fibrotic or fibrocalcific lesion types.98 Stent underexpansion leads to shear stress 
concentration on the edges of the stent struts and higher jet and shear rate in the underexpanded segment, 
which may increase the risk of stent thrombosis.99 Stent underexpansion has been commonly associated with 
early stent thrombosis (>30 days).100–102 Fujii et al101 conducted an analysis on 15 patients admitted for stent 
thrombosis and compared them with 45 matched control patients with no stent thrombosis. The study 
showed that the stent cross-sectional area was significantly smaller in the stent thrombosis group than in the 
matched control patients (4.3±1.6 versus 6.2±1.9 mm2).101 
Another study sought to compare the acute gain and late lumen loss between Absorb BVS and DES at 2-year 
followup. Thirty-three patients implanted with BVS and 26 patients implanted with the DES from the ABSORB 
B (ABSORB Clinical Investigation, Cohort B) and SPIRIT II (A Clinical Evaluation of the XIENCE V® Everolimus 
Eluting Coronary Stent System) trials were examined. Analysis showed similar acute gain (BVS: 1.23±0.38 mm 
versus DES: 1.32±0.26 mm; P=0.29) and similar in device late lumen loss at 2-year follow-up (BVS: 0.26±0.19 
mm versus DES: 0.22±0.22 mm; P=0.29). However, patients implanted with BVS showed significantly lower in 
stent minimum lumen diameter compared with patients implanted with DES (BVS: 2.02±0.26 mm versus DES: 
2.22±0.34 mm; P=0.01).103 Suwannasom et al104 investigated the postprocedural asymmetry, expansion, and 
eccentricity indices between DES and BVS and their impact on clinical outcomes at 1-year follow-up. Pre- and 
postprocedural intravascular ultrasound images from 470 patients were used to calculate the asymmetry 
index per lesion and eccentricity index per cross-section. DES was more symmetrical and concentric compared 
with the BVS group post procedure, with only 8% of BVS compared with 20% of DES achieving optimal 
scaffold/stent expansion (P<0.001). Although there was no difference in device-oriented composite end point 
at 1-year follow-up (BVS=5.2% versus DES=3.1%; P=0.29), postprocedural device asymmetry was associated 
with increased event rates, with analysis showing that asymmetry index >0.30 was an independent predictor 
of device-oriented composite end point (hazard ratio: 3.43; P=0.037). 
In a recent study, Foin et al105 compared the acute expansion behavior of DES and Absorb BVS in an in vitro 
artery lesion model. Results showed that stent eccentricity at the minimum lumen area was lower in the BVS 
compared with Xience metallic stent when deployed at nominal pressure (BVS: 0.71±0.02 versus Xience: 
0.81±0.02; P=0.004). These anatomic differences were associated with increased shear rate and increased 
recirculation zones at the downstream of the underexpanded segment.105 Computational fluid dynamic 
models have also demonstrated that even at the same diameter stenosis, an eccentric lesion induces larger 
recirculation. Therefore, when the stent is not symmetrically expanded, intravascular imaging should be 
considered to assess the final result.106 
Scaffold underexpansion has been shown to be also a predictor of events in the Absorb BVS. Puricel et al84 
investigated the incidence, clinical and angiographic features, as well as the possible mechanisms of stent 
thrombosis in 1305 patients implanted with BVS. The study revealed that a low postprocedural minimum 
lumen diameter and low reference diameters were predictors of stent thrombosis.84 The risk of stent 
thrombosis increased rapidly for minimum lumen diameter <2.4 mm for the 2.5- to 3.0-mm BVS and <2.8 mm 
for BVS that had a 3.5-mm diameter.84 However, when aggressive lesion preparation and aggressive device 
postdilatation was implemented, scaffold thrombosis at 1-year follow-up fell from 3.3% to 1.0% (P=0.012),84 





Malapposition, also known as incomplete stent apposition (ISA), can affect local flow and shear profile in the 
stented vessel. A stent strut is considered malapposed when is not in contact with the vessel wall. Malapposed 
stent struts disrupt the laminar flow and can generate regions of high shear rate (Figures 4 and 5)10,11,13 which 
are known to affect the risk of stent thrombosis.11,77,107 In an in vitro experiment, Kolandaivelu et al11 showed 
that malapposed BMS showed a 1.5-fold increase in thrombogenicity compared with wellapposed stents 
(P=0.001). 
Malapposition also reduces stent strut coverage. A recent study analyzed the impact of baseline strut-vessel 
wall ISA distance on strut coverage at follow-up. As ISA increases from <100 μm to 100 to 300 μm and finally 
to >300 μm, the percentage of uncovered struts at follow-up increased from 0% to 6.1% and 15.7%, 
respectively.10 
Recently, reports have pointed to ISA as a possible mechanism leading to scaffold thrombosis in BRS.109–112 In 
one study, Gomez-Lara et al showed that malapposed BRS struts are more frequently uncovered compared 
with apposed struts (29% of ISA struts versus 1% of apposed struts) and that intraluminal masses (possible 
thrombus) were seen in malapposed BRS struts more often as compared with apposed struts (39% of ISA struts 
versus 2% apposed struts).93,113–115 Computational fluid dynamic analysis on stented/scaffolded segments 
demonstrated higher shear profiles in BRS compared with thin metallic DES, hence underlining the importance 
of imaging guidance, optimal expansion, and apposition during BRS implantation.99 
 
Conclusion 
To summarize, suboptimal stent implantation affects the local hemodynamic forces and can lead to 
unfavorable clinical outcomes. Regions of low ESS after PCI are colocated with neointima and 
neoatherosclerosis formation. High shear gradients and flow disturbances have been shown to increase the 
risk of thrombosis. Therefore, effort should be made to optimize stent deployment and stent/scaffold designs 
to ensure an optimal hemodynamic profile and reduce the risk of complications after PCI. 
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Regions of low ESS showed progressive atherosclerosis and 
outward remodelling. 





Compared to moderate/high ESS, low ESS showed plaque 
progression (p=0.009). 





Regions of low ESS developed progression of plaque area 
(p=0.027), necrotic core (p<0.001) and decrease in vessel 
(p<0.001) and lumen area (p<0.001) as compared to regions 
of intermediate ESS. 
Compared to intermediate ESS, high ESS developed 
progression of necrotic core (p<0.001), dense calcium 
(p<0.001) regression of fibrous (p<0.001) and fibrofatty 
(p<0.001) tissue and increase in vessel (p<0.001) and lumen 
area (p<0.001). 





Low ESS is associated with plaque enlargement and lumen 
narrowing, the main message being ESS is a predictor of 
clinical outcomes. 





Regions exposed to low ESS is linked to larger lipid burden 
(p=0.019), thinner fibrous cap (p=0.004) and higher prevalence 
of thin-cap fibroatheroma (p=0.037). 





Low ESS was linked to plaque progression (p<0.0001) and 
constrictive remodelling (p=0.04). 
Restenosis 





Neointimal thickness at follow up is inversely related to shear 
stress in BMS. Thickness = 0.59– 0.08*Shear Stress, p < 0.05. 






There was a negative linear relation between neointimal 
thickness and shear stress. Thickness = 0.21 – 0.24*Shear 
Stress, R2=0.24, p < 0.001. 





In stent restenosis is inversely related to ESS after coronary 
with the equation: Thickness = 0.28– 0.057*Shear Stress, 
p<0.001. Vascular brachytherapy diminishes the inverse 
relationship between restenosis and ESS. 
Papafaklis et al. 
(2010)53 
30 6 IVUS 
Low ESS is inversely related to neointimal thickness for both 
BMS (slope = -0.05mm/Pa, p = 0.001) and DES (slope = -
0.05mm/Pa, p = 0.016). 
Bourantas et al. 
(2014)54 
6 6 or 12 
Angiography, 
OCT, IVUS 
In scaffolded segments models the ESS estimated by the 
fusion of IVUS and X-ray angiography differs from the ESS 
derived from the fusion of OCT and X-ray imaging. The 
correlation coefficient between ESS and neointima thickness is 
increased in OCT based modelling comparing to IVUS based 
reconstructions.   
Bourantas et al. 
(2014)55 
12 12 OCT 
Low ESS was associated with increased neointima thickness 
at 1 year follow up in BRS (correlation coefficient range: -0.140 
to -0.662). 





ESS determines neointimal formation in both BMS (p < 0.001) 
and BES (p=0.002) and is a predictor of an increased necrotic 
core component in BMS. 





Low ESS after BMS implantation is associated with in stent 
hyperplasia. Post PCI ESS is not associated with in stent 
restenosis requiring repeat PCI. 
A summary on patient studies that look the effect of shear stress on atherosclerosis and restenosis. Most 
atherosclerosis showed an inverse association between ESS and plaque or neointima burden. BES indicates biolimus 
eluting stents; BMS, bare metal stents; BRS, bioresorbable scaffolds; ESS, endothelial shear stress; IVUS, intravascular 




Figure 1. Optical coherence tomography (OCT)–based reconstruction and blood flow simulation immediately after 
scaffold implantation. This is an example of the use of high-resolution imaging modalities for the prediction of local 
hemodynamics and endothelial shear stress (ESS) after Absorb bioresorbable vascular scaffold (BVS) implantation. A 
magnified view of the OCT-derived lumen surface (A), revealing the strut architecture in the OCT-derived lumen 
surface (B). Protruding struts affect the local ESS distribution with higher values noted on top of the struts and lower 
values in the interstrut areas (B). Flow streamlines in a longitudinal cross-section (C); flow disturbance and 
recirculation regions around the struts regions (arrow and dotted arrow). Corresponding OCT cross-sectional images 
(evident by the side branch [br]) at baseline (D), ESS distribution (E), and 2-y follow-up (F). Intravascular ultrasound 
(IVUS)–based reconstruction of the scaffolded segment at baseline with the ESS shown in a color-coded map (G). IVUS 
cross-sectional images at baseline (H) and 2-y followup (J) corresponding to the OCT images. The lower IVUS resolution 
allows a rough assessment of BVS struts (*) and cannot detect the neointima tissue. Note the smoother ESS distribution 
compared with the OCT-based model. A stronger correlation was noted between the baseline ESS and neointima 
thickness at 2 y in the OCT-based model (K, R2=0.50) compared with the IVUS-based reconstruction (L, R2=0.13). 





Figure 2. Shear rate and endothelial shear stress (ESS) definition. Shear rate is the velocity gradient along the diameter 
of the vessel. ESS is derived from the velocity gradient near the wall (shear rate) multiplied by the viscosity of the blood 
(μ). It has the dimension of force per unit area and is expressed generally in Pascal or dyne/cm2 (1 Pa=10 dyne/cm2). 
In a straight cylindrical vessel of a radius r with a developed parabolic laminar flow profile (Poiseuille flow), ESS can be 
evaluated from the Hagen–Poiseuille equation: ESS=4Q⋅μ/ (πr3), where Q is the flow-rate, μ the fluid viscosity, r the 
tube radius. Adapted from Foin et al5 with permission. Copyright ©2017. 
 
 
Figure 3. Correlation between baseline endothelial share stress (ESS) and thickness of neointima in a patient with 3.7 
y of follow-up after stent implantation. A, ESS map on the baseline 3-dimensional vascular model (transparent) and 
vessel anatomy at the follow-up (gray surface inside). B, Point-to-point association between the baseline ESS and 
neointimal thickness within the stented segment, showing inverse-proportional correlation. C, Spread-out plots of ESS 
(top) and neointimal thickness (bottom) in the stented segment, demonstrating spatial relationship between low ESS 





Figure 4. Stent strut protrusion and thrombosis. Embedded struts disrupt blood flow the least out of the 3 scenarios 
and has the lowest area of recirculation and physiological levels of shear rate. Hence, activator proteins like vWF (Von 
Willebrand factor) are not activated, and platelet adhesion and aggregation remain at a minimum. Malapposed struts 
have regions of high shear rate both at the top and bottom of the strut and a larger surface area for adhesion proteins 
to bind to, creating a thrombogenic surface as compared with a protruding strut. At high shear rates, platelets are 
activated via the vWFbinding to glycoprotein (GP) lb and GP llb/llla receptors13,108 resulting in clot formation and 







Figure 5. Impact of strut thickness on blood flow profiles for model simulating case of well-apposed and malapposed 
drug-eluting stents (DES) and bioresorbable scaffolds (BRS) struts. A, Simulated blood flow streamlines (top) for the 
different cases of strut apposition: (1) apposed and (2) malapposed (with strut to wall distance=300 μm). Models are 
representative of a 3-mm diameter straight coronary artery flow with a parabolic upstream velocity profile and a peak 
velocity of 50 cm/s. The 2 strut thicknesses are considered to correspond to a total strut thickness (strut+coating) of 
156 μm (Absorb BVS) and 97 μm (Xience DES). B, Corresponding shear rate profile in blood around stent strut simulated 
for each case (bottom) shows that flow disturbances and high shear rates (red) are increased primarily in thicker and 
malapposed struts. Reprinted from Foin et al99 with permission. Copyright ©2015, Europa Digital & Publishing. 
